Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of TXA127 in hospitalized COVID-19 patients

Next Previous
X
Search
Trial Profile

Phase II trial of TXA127 in hospitalized COVID-19 patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 18 May 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Angiotensin-1-7 (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Acronyms ACTIV-4d

    • Most Recent Events

    • 12 May 2021 According to a Constant Therapeutics media release, Sean Collins, MD, MSci, Co-Director of the Vanderbilt Coordinating Center and Professor of Emergency Medicine, Vanderbilt University Medical Center (VUMC) is the Principal Investigator of this trial
    • 12 May 2021 According to a Constant Therapeutics media release, TXA127 for COVID-19 To Enter NIH-Funded Clinical Trial At 60 Sites Around The U.S.
    • 14 Jul 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top